title: Effect of doxazosin in mild to moderate hypertensive patients with insulin-dependent diabetes mellitus.
abstract: Diabetic patients often develop hypertension, and the presence of both hypertension and diabetes doubles the risk of death from coronary heart disease (CHD). Moreover, the presence and importance of abnormalities such as high low-density lipoprotein (LDL) cholesterol and triglycerides levels as CHD risk factors in insulin-dependent diabetes mellitus type 1 have been downplayed, while increasing evidence suggests that the management of type 1 patients should include control of dyslipidemia and hyperglycemia and an effective antihypertensive treatment able also to reduce risk factors for coronary artery events. In this study we assessed the antihypertensive and metabolic effects of doxazosin in hypertensive patients with type 1 diabetes. We show that the drug normalizes blood pressure, and while no improvement in glucose control was observed, it reduced total cholesterol and increased HDL cholesterol as well as the HDL to total cholesterol ratio. The changes of the various parameters studied, including the calculated CHD risk score based on the Framingham equation, suggest that doxazosine can reduce the CHD risk for hypertensive type 1 patients.
authors.affiliation: Institute of Internal Medicine, Division of Nephrology, University of Padova, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Calò
authors.forename: P A
authors.initials: PA
authors.lastname: Davis
authors.forename: S
authors.initials: S
authors.lastname: Cantaro
authors.forename: L
authors.initials: L
authors.lastname: Bonfante
authors.forename: R
authors.initials: R
authors.lastname: Castrignano
authors.forename: G
authors.initials: G
authors.lastname: Carraro
authors.forename: A
authors.initials: A
authors.lastname: D'Angelo
mesh_terms: D000293:Adolescent; D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D003327:Coronary Disease / Q000209:etiology; D003922:Diabetes Mellitus, Type 1; D003925:Diabetic Angiopathies / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology*; D017292:Doxazosin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D012307:Risk Factors
chemical_list: D000317:Adrenergic alpha-Antagonists; D008055:Lipids; D017292:Doxazosin